| Title |
“ACHILLES” Heel No More? Afatinib at 40 Mg Once Daily is Superior to Platinum-Based Chemotherapy in EGFR Uncommon (G719X, S768I, and L861Q) Mutations (ACHILLES/TORG1834)
|
|---|---|
| Published in |
Lung Cancer: Targets and Therapy, May 2024
|
| DOI | 10.2147/lctt.s461758 |
| Pubmed ID | |
| Authors |
Faustine X Luo, Sai-Hong Ignatius Ou |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 May 2024.
All research outputs
#23,797,834
of 26,491,397 outputs
Outputs from Lung Cancer: Targets and Therapy
#122
of 136 outputs
Outputs of similar age
#277,168
of 338,744 outputs
Outputs of similar age from Lung Cancer: Targets and Therapy
#5
of 6 outputs
Altmetric has tracked 26,491,397 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 136 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.6. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 338,744 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 6 others from the same source and published within six weeks on either side of this one.